Yomeishu Seizo Co.,Ltd.
Notice Regarding Application to Tender Offer and Recording of Extraordinary Income (Expected)
Yomeishu Seizo plans to apply its 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. in Taiyo Kosan's tender offer at approximately 6,082 yen/share, totaling about 614 million yen. An extraordinary income of approximately 413 million yen is expected to be recorded in the fiscal year ending March 2026.
Key Figures
- Number of shares to be tendered: 101,000 shares
- Planned purchase price: 6,082 yen/share
- Planned total sale amount: 614 million yen
- Expected recording of extraordinary income: 413 million yen
AI要約
Reason for Applying to the Tender Offer
Yomeishu Seizo Co., Ltd. has resolved to apply the 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. it owns to the tender offer conducted by Taiyo Kosan Co., Ltd. Based on the board of directors’ decision and the supportive opinion of Hisamitsu Pharmaceutical’s board, the purchase price and other conditions were judged reasonable, and it was determined that this contributes to enhancing corporate value.
Number of Shares to be Tendered, Purchase Price, and Future Outlook
The number of shares to be tendered is 101,000 shares, resulting in zero shares owned post-application. The planned purchase price is 6,082 yen per share, with a planned total sale amount of 614 million yen. The tender offer period is scheduled from January 7, 2026, to February 19, 2026, with settlement starting on February 27, 2026. From this sale, an extraordinary gain of 413 million yen as investment securities sale profit is expected to be recorded in the fiscal year ending March 2026, with no revision to earnings guidance.
